Spark Therapeutics, Inc. (ONCE) CEO Sells $1,126,500.00 in Stock
Spark Therapeutics, Inc. (NASDAQ:ONCE) CEO Jeffrey D. Marrazzo sold 15,000 shares of the business’s stock in a transaction dated Friday, August 11th. The stock was sold at an average price of $75.10, for a total transaction of $1,126,500.00. Following the transaction, the chief executive officer now owns 245,000 shares in the company, valued at $18,399,500. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.
Shares of Spark Therapeutics, Inc. (NASDAQ ONCE) traded down 1.82% during mid-day trading on Tuesday, hitting $78.16. 446,546 shares of the company traded hands. The stock’s market capitalization is $2.44 billion. Spark Therapeutics, Inc. has a one year low of $35.07 and a one year high of $80.89. The firm has a 50-day moving average of $67.65 and a 200-day moving average of $60.03.
Spark Therapeutics (NASDAQ:ONCE) last posted its quarterly earnings data on Wednesday, August 2nd. The biotechnology company reported ($1.89) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.75) by $0.14. Spark Therapeutics had a negative return on equity of 59.74% and a negative net margin of 962.72%. The company had revenue of $1.48 million for the quarter, compared to analysts’ expectations of $1.33 million. During the same quarter last year, the business posted ($1.04) EPS. The business’s quarterly revenue was up 14.7% on a year-over-year basis. On average, equities analysts predict that Spark Therapeutics, Inc. will post ($7.49) earnings per share for the current year.
COPYRIGHT VIOLATION NOTICE: “Spark Therapeutics, Inc. (ONCE) CEO Sells $1,126,500.00 in Stock” was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this news story on another domain, it was illegally stolen and reposted in violation of international trademark and copyright legislation. The original version of this news story can be read at https://www.thecerbatgem.com/2017/08/15/spark-therapeutics-inc-once-ceo-sells-1126500-00-in-stock.html.
A number of hedge funds have recently bought and sold shares of ONCE. Norges Bank bought a new stake in Spark Therapeutics during the fourth quarter worth about $8,232,000. UBS Asset Management Americas Inc. increased its stake in Spark Therapeutics by 6.1% in the fourth quarter. UBS Asset Management Americas Inc. now owns 185,036 shares of the biotechnology company’s stock worth $9,233,000 after buying an additional 10,616 shares during the period. Teachers Advisors LLC increased its stake in Spark Therapeutics by 16.8% in the fourth quarter. Teachers Advisors LLC now owns 33,884 shares of the biotechnology company’s stock worth $1,691,000 after buying an additional 4,875 shares during the period. Fox Run Management L.L.C. bought a new stake in Spark Therapeutics during the first quarter worth about $944,000. Finally, Nationwide Fund Advisors increased its stake in Spark Therapeutics by 2.5% in the first quarter. Nationwide Fund Advisors now owns 17,298 shares of the biotechnology company’s stock worth $923,000 after buying an additional 414 shares during the period. Institutional investors and hedge funds own 87.30% of the company’s stock.
Several research firms have recently weighed in on ONCE. Chardan Capital upgraded shares of Spark Therapeutics from a “neutral” rating to a “buy” rating and boosted their price objective for the stock from $60.00 to $100.00 in a research note on Tuesday, August 8th. Zacks Investment Research lowered shares of Spark Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, August 5th. Stifel Nicolaus restated a “buy” rating and set a $92.00 price objective (up from $77.00) on shares of Spark Therapeutics in a research note on Thursday, August 3rd. Cowen and Company restated an “outperform” rating and set a $95.00 price objective (up from $75.00) on shares of Spark Therapeutics in a research note on Thursday, August 3rd. Finally, Jefferies Group LLC restated a “buy” rating and set a $95.00 price objective (up from $85.00) on shares of Spark Therapeutics in a research note on Thursday, August 3rd. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and twelve have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $82.27.
About Spark Therapeutics
Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.
Receive News & Stock Ratings for Spark Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics Inc. and related stocks with our FREE daily email newsletter.